| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 02/20/2003 | WO2003013440A2 Treatment and prevention of heat shock protein-associated diseases and conditions |
| 02/20/2003 | WO2003013434A2 Methods and compositions for treating diseases associated with excesses in ace |
| 02/20/2003 | WO2003013432A2 Methods of use for novel sulfur containing organic nitrate compounds |
| 02/20/2003 | WO2003013423A2 Antithrombotic agent |
| 02/20/2003 | WO2003013420A2 Isoprenyl derivatives and their use in the treatment and prevention of osteoporosis and cardiovascular calcification |
| 02/20/2003 | WO2002102794A3 Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 02/20/2003 | WO2002096927A3 Ribozyme based treatment of female reproductive diseases |
| 02/20/2003 | WO2002096516A8 Use of compositions comprising cyclooxygenase-2 selective inhibitors in combination with radiation for inhibition or prevention of cardiovascular disease |
| 02/20/2003 | WO2002094862A3 Hypoxia inducible factors and uses thereof for inducing angiogenesis and improving muscular functions |
| 02/20/2003 | WO2002086085A3 Human timp-1 antibodies |
| 02/20/2003 | WO2002085368A3 Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders |
| 02/20/2003 | WO2002083733A3 Polynucleotides and polypeptides of the ifnalpha-6 gene |
| 02/20/2003 | WO2002074742A3 Cdk-inhibitory indirubin derivatives having an increased solubility |
| 02/20/2003 | WO2002072585A3 Substituted pyrazolopyrimidines and thiazolopyrimidines used as analgesics |
| 02/20/2003 | WO2002068399B1 Aryl carbamate derivatives, preparation and use thereof |
| 02/20/2003 | WO2002066505A3 Gmg-3, gmg-4, and gmg-6 polynucleotides and polypeptides and uses thereof |
| 02/20/2003 | WO2002064126A3 Method of treating of demyelinating diseases or conditions |
| 02/20/2003 | WO2002064109A3 Mucoadhesive pharmaceutical formulations |
| 02/20/2003 | WO2002064026A3 Treating pulmonary disorders with gaseous agent causing repletion of gsno |
| 02/20/2003 | WO2002053170A3 Combined use of enzyme inhibitors and pharmaceutical preparations thereof for the treatment and prophylaxis of arteriosclerosis, for the treatment and prevention of allergic reactions of type i according to the gell and coombs classification, and for the treatment and prevention of dermatological diseases associated with fo |
| 02/20/2003 | WO2002053090A3 Medicinal association of a biguanine (metformin) and arginine |
| 02/20/2003 | WO2002049993A3 High affinity small molecule c5a receptor modulators |
| 02/20/2003 | WO2002042295A3 Peptides as met-ap2 inhibitors |
| 02/20/2003 | WO2002032842A9 Compounds with high monoamine transporter affinity |
| 02/20/2003 | WO2002030882A9 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
| 02/20/2003 | WO2002030860A9 Ketone compounds and compositions for cholesterol management and related uses |
| 02/20/2003 | WO2002029088A9 Highly expressible genes |
| 02/20/2003 | WO2002024635A3 Aminoalcohol derivatives |
| 02/20/2003 | WO2002022621B1 INTERPHENYLENE 7-OXABICYCLIC[2.2.1]HEPTANE OXAZOLES AS PROSTAGLANDIN F2a ANTAGONISTS |
| 02/20/2003 | WO2002014368A8 Proteins and nucleic acids encoding the same |
| 02/20/2003 | US20030036652 Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines |
| 02/20/2003 | US20030036651 As phosphodiesterase inhibitor for prophylaxis and therapy of bronchial asthma; pneumonic diseases, pulmonary emphysema, chronic obstructive pulmonary disease acute respiratory distress syndrome (ARDS), and other respiratory diseases |
| 02/20/2003 | US20030036642 Platelet derived growth factor (PDGF) nucleic acid ligand complexes |
| 02/20/2003 | US20030036633 DNA encoding bradykinin B1 receptor |
| 02/20/2003 | US20030036552 Novel compounds |
| 02/20/2003 | US20030036543 Especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease. |
| 02/20/2003 | US20030036512 A neurotrophic factor, such as brain-derived neurotrophic factor; treating leptin resistance caused hypertension, sterility, obesity, glucose metabolic abnormality, ischemic disease and growth hormone insufficiency |
| 02/20/2003 | US20030036507 Urocortin-III and uses thereof |
| 02/20/2003 | US20030036504 Modululation of both fasting and postprandial lipid levels. |
| 02/20/2003 | US20030036208 Drug screening and diagnosis based on paracrine tubular renin-angiotensin system |
| 02/20/2003 | US20030036075 Nucleotide sequences coding transport protein for us in the treatment and diagnosis of cancer, arthritis, vision defects and skin dsorders |
| 02/20/2003 | US20030035850 Hemorrhoidal compositions and method of use |
| 02/20/2003 | US20030035836 Oral controlled release pharmaceutical composition for once-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases |
| 02/20/2003 | US20030035835 Protective overcoatings |
| 02/20/2003 | US20030035832 Compression of drug and adjuvant |
| 02/20/2003 | US20030035787 Polyanhydrides with biologically active degradation products |
| 02/20/2003 | CA2607992A1 Bicyclic compound, production and use thereof |
| 02/20/2003 | CA2462200A1 Peptidomimetics of biologically active metallopeptides |
| 02/20/2003 | CA2457400A1 Modulation of leukocyte-endothelial interactions following ischemia |
| 02/20/2003 | CA2456881A1 Somatostatin analogues and their use somatostatin analogues binding to all somatostatin receptor and their use |
| 02/20/2003 | CA2456762A1 Interleukin-1 receptors in the treatment of diseases |
| 02/20/2003 | CA2456744A1 Adenosine a3 receptor agonists |
| 02/20/2003 | CA2456599A1 Spiro compounds |
| 02/20/2003 | CA2456533A1 Histone deacetylase enzyme-inhibiting derivatives of hydroxamic acid as new cytokine synthesis-inhibiting anti-inflammatory drugs |
| 02/20/2003 | CA2456288A1 Fatty acid compounds, preparation and uses thereof |
| 02/20/2003 | CA2456287A1 Anti-idiotypic antibodies of hla class i molecules and the use thereof in the preparation of compositions that are designed to inhibit vascular activation |
| 02/20/2003 | CA2456223A1 Regulation of the apj receptor for use in the treatment or prophylaxis of cardiac diseases |
| 02/20/2003 | CA2456175A1 Benzoquinone ansamycins |
| 02/20/2003 | CA2456124A1 Substituted 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid derivatives serving as nmda antagonists |
| 02/20/2003 | CA2456103A1 Salts of substituted 1, 2, 3, 4-tetrahydroquinoline-2-carboxylic acid derivatives |
| 02/20/2003 | CA2456034A1 Sustained-release medicines |
| 02/20/2003 | CA2455761A1 Artichoke leaf extracts |
| 02/20/2003 | CA2455759A1 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| 02/20/2003 | CA2455754A1 Amine derivatives |
| 02/20/2003 | CA2455631A1 Aminoisoxazole derivatives active as kinase inhibitors |
| 02/20/2003 | CA2455498A1 Antisense modulation of apolipoprotein(a) expression |
| 02/20/2003 | CA2455336A1 Peptides that bind to atherosclerotic lesions |
| 02/20/2003 | CA2454519A1 Hprp4s as modifiers of the p53 pathway and methods of use |
| 02/20/2003 | CA2454514A1 Sphks as modifiers of the p53 pathway and methods of use |
| 02/20/2003 | CA2454417A1 Novel benzo-fused heterocycles as endothelin antagonists |
| 02/20/2003 | CA2454251A1 Isolation and mobilization of stem cells expressing vegfr-1 |
| 02/20/2003 | CA2453995A1 Tacis and br3 polypeptides and uses thereof |
| 02/20/2003 | CA2453890A1 Crystal and process for producing the same |
| 02/20/2003 | CA2453884A1 Micronutrient phosphates as dietary and health supplements |
| 02/20/2003 | CA2453433A1 Methods of use for novel sulfur containing organic nitrate compounds |
| 02/20/2003 | CA2451919A1 Nucleic acids, polypeptides, single nucleotide polymorphisms and methods of use thereof |
| 02/19/2003 | WO2002016574A2 Method for identifying peptides that can be specifically cleaved and the use of peptide sequences of this type |
| 02/19/2003 | EP1284423A2 Adrenic acid (delta 7,10,13,16 docosatetraenoic acid ) receptor and uses thereof |
| 02/19/2003 | EP1284268A1 Thiazolidinedione derivative and its use as antidiabetic |
| 02/19/2003 | EP1284266A1 Novel indole derivatives exhibiting chymase-inhibitory activities and process for preparation thereof |
| 02/19/2003 | EP1284265A1 Benzothiophene derivatives and medicinal use thereof |
| 02/19/2003 | EP1284141A2 Pharmaceutical combinations comprising neuronal nitric oxide synthase inhibitors for the treatment of neurodegenerative diseases |
| 02/19/2003 | EP1284139A1 Novel fatty acid analogues for the treatment of fatty liver |
| 02/19/2003 | EP1283894A1 Use of baculovirus vectors in gene therapy |
| 02/19/2003 | EP1283886A2 Intracellular signaling proteins |
| 02/19/2003 | EP1283848A2 Protein complexes and assays for screening anti-cancer agents |
| 02/19/2003 | EP1283835A2 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as protein kinase modulators |
| 02/19/2003 | EP1283834A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 02/19/2003 | EP1283833A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 02/19/2003 | EP1283832A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 02/19/2003 | EP1283831A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 02/19/2003 | EP1283828A1 Novel polymorph v of torasemide |
| 02/19/2003 | EP1283827A2 Caspase inhibitors and uses thereof |
| 02/19/2003 | EP1283825A1 N-substituted peptidyl nitriles as cysteine cathepsin inhibitors |
| 02/19/2003 | EP1283823A1 Novel mmp-2/mmp-9 inhibitors |
| 02/19/2003 | EP1283723A2 Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor |
| 02/19/2003 | EP1283715A1 Modulaton of alpha-6 integrin-mediated responses |
| 02/19/2003 | EP1283707A1 Polymerizable compositions and methods of use |
| 02/19/2003 | EP1283706A1 Dosage of transdermal delivery systems |
| 02/19/2003 | EP1283672A1 Antitubulin assembly and cell growth inhibitor denominated "dioxostatin" |